Abstract
Parkinsons disease (PD) is a neurological disorder characterized by the progressive impairment of motor skills in patients. Growing evidence suggests that abnormal redox-active metal accumulation, caused by dysregulation, plays a central role in the neuropathology of PD. Redox-active metals (e.g. Fe and Cu) catalyze essential reactions for brain function. However, these metals can also participate in the generation of highly toxic free radicals that can cause oxidative damage to cells and ultimately lead to the death of dopamine-containing neurons. The emergence of redox-active metals as key players in the pathogenesis of PD strongly suggests that metal-chelators could be beneficial in the treatment of this condition. This mini-review summarizes major recent developments on natural, synthetic iron chelating compounds and hydrogen peroxide-triggered prochelators as potential candidates for PD treatment.
Keywords: Parkinson's disease, iron, chelator, polyphenol, fenton reaction, free radicals
Current Bioactive Compounds
Title: Iron Chelators as Potential Therapeutic Agents for Parkinsons Disease
Volume: 4 Issue: 3
Author(s): Carlos A. Perez, Yong Tong and Maolin Guo
Affiliation:
Keywords: Parkinson's disease, iron, chelator, polyphenol, fenton reaction, free radicals
Abstract: Parkinsons disease (PD) is a neurological disorder characterized by the progressive impairment of motor skills in patients. Growing evidence suggests that abnormal redox-active metal accumulation, caused by dysregulation, plays a central role in the neuropathology of PD. Redox-active metals (e.g. Fe and Cu) catalyze essential reactions for brain function. However, these metals can also participate in the generation of highly toxic free radicals that can cause oxidative damage to cells and ultimately lead to the death of dopamine-containing neurons. The emergence of redox-active metals as key players in the pathogenesis of PD strongly suggests that metal-chelators could be beneficial in the treatment of this condition. This mini-review summarizes major recent developments on natural, synthetic iron chelating compounds and hydrogen peroxide-triggered prochelators as potential candidates for PD treatment.
Export Options
About this article
Cite this article as:
Perez A. Carlos, Tong Yong and Guo Maolin, Iron Chelators as Potential Therapeutic Agents for Parkinsons Disease, Current Bioactive Compounds 2008; 4 (3) . https://dx.doi.org/10.2174/157340708786305952
DOI https://dx.doi.org/10.2174/157340708786305952 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNAs in Genetic Disease: Rethinking the Dosage
Current Gene Therapy Inhibition of Monoamine Neurotransmitter Transporters andCentral Nervous System Stimulation Induced by Synthetic Local Anesthetics and Cocaine: A Comparative Review
Current Medicinal Chemistry - Central Nervous System Agents Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine
Current Drug Metabolism MicroRNAs: Emerging Role in the Endogenous μ Opioid System
CNS & Neurological Disorders - Drug Targets Structure-Function Relationships of Antimicrobial Peptides and Proteins with Respect to Contact Molecules on Pathogen Surfaces
Current Topics in Medicinal Chemistry Plausible Improvements for Selective Targeting of Dopamine Receptors in Therapy of Parkinson’s Disease
Mini-Reviews in Medicinal Chemistry The Effect of Lipopolymer Structure on the Transfection Efficiency of Hydrophobic Polyethylenimine-based Cationic Nanoliposomes
Current Nanoscience Neuroprotective Properties of Erythropoietin in Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Endocrine Disruptors and Human Health
Mini-Reviews in Medicinal Chemistry Recent Inventions on Receptor Tyrosine Kinase RET Modulation
Recent Patents on Biotechnology The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma
Current Cancer Drug Targets Genetic and Epigenetic Regulation of Phosphoinositide 3-kinase Isoforms
Current Pharmaceutical Design Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators
Current Topics in Medicinal Chemistry <i>Piper sarmentosum</i> Roxb. Attenuates Beta Amyloid (Aβ)-Induced Neurotoxicity <i>Via</i> the Inhibition of Amyloidogenesis and Tau Hyperphosphorylation in SH-SY5Y Cells
Current Alzheimer Research Unique Medicinal Properties of Withania somnifera: Phytochemical Constituents and Protein Component
Current Pharmaceutical Design Molecular Mechanisms of Action of Gas1 and its Possible Therapeutic Applications
Current Signal Transduction Therapy Influence of Early Life Lead (Pb) Exposure on α-Synuclein, GSK-3β and Caspase-3 Mediated Tauopathy: Implications on Alzheimer’s Disease
Current Alzheimer Research Hematopoietic Stem Cells Therapies
Current Stem Cell Research & Therapy The Potency of Refined Mouse Models: Implications for Clinical Trials
Current Cancer Therapy Reviews Sphingolipid Signaling and Hematopoietic Malignancies: To the Rheostat and Beyond
Anti-Cancer Agents in Medicinal Chemistry